PubRank

Phase Ib of Abiraterone Acetate Plus BEZ235 or BKM120 in Castration-resistant Prostate Cancer (CRPC) Patients

Clinical Trial ID NCT01634061

PubWeight™ 13.97‹?›

🔗 Visit the ClinicalTrials.gov page for NCT01634061

Top papers

Rank Title Journal Year PubWeight™‹?›
1 What a tangled web we weave: emerging resistance mechanisms to inhibition of the phosphoinositide 3-kinase pathway. Cancer Discov 2013 1.38
2 Targeting the androgen receptor pathway in castration-resistant prostate cancer: progresses and prospects. Oncogene 2014 1.31
3 PI3K-AKT-mTOR signaling in prostate cancer progression and androgen deprivation therapy resistance. Asian J Androl 2014 1.23
4 Molecular pathways and targets in prostate cancer. Oncotarget 2014 1.00
5 Targeting the adaptive molecular landscape of castration-resistant prostate cancer. EMBO Mol Med 2015 0.93
6 Growth factor and signaling pathways and their relevance to prostate cancer therapeutics. Cancer Metastasis Rev 2014 0.92
7 Challenges in the clinical development of PI3K inhibitors. Ann N Y Acad Sci 2013 0.91
8 Targeting the androgen receptor in the management of castration-resistant prostate cancer: rationale, progress, and future directions. Curr Oncol 2012 0.89
9 Targeting the androgen receptor in prostate and breast cancer: several new agents in development. Endocr Relat Cancer 2015 0.89
10 Androgen synthesis inhibitors in the treatment of castration-resistant prostate cancer. Asian J Androl 2014 0.86
11 CYP17A1 inhibitors in castration-resistant prostate cancer. Steroids 2015 0.84
12 Resistance to Novel Antiandrogen Therapies in Metastatic Castration-Resistant Prostate Cancer. Clin Med Insights Oncol 2016 0.83
13 Androgen pathway resistance in prostate cancer and therapeutic implications. Expert Opin Pharmacother 2015 0.77
14 Translational and clinical implications of the genetic landscape of prostate cancer. Nat Rev Clin Oncol 2016 0.76
15 Therapeutic interventions to disrupt the protein synthetic machinery in melanoma. Pigment Cell Melanoma Res 2015 0.75
Next 100